Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
The Clinical Picture

5-Fluorouracil–induced encephalopathy

Yudai Yano, MD and Akira Kuriyama, MD, MPH
Cleveland Clinic Journal of Medicine September 2020, 87 (9) 532-533; DOI: https://doi.org/10.3949/ccjm.87a.19126
Yudai Yano
Emergency and Critical Care Center, Kurashiki Central Hospital, Okayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akira Kuriyama
Emergency and Critical Care Center, Kurashiki Central Hospital, Okayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

A 40-year-old woman presented with altered mental status, having been found by her family after she had been in the bathroom for more than 7 hours. She was on chemotherapy with mFOLFOX6 for metastatic rectal cancer. Her regimen consisted of 5-fluorouracil (5-FU) in a 400-mg/m2 bolus and 2,400 mg/m2 by continuous infusion for 3 days, levofolinate 200 mg/m2, and oxaliplatin 85 mg/m2. She was currently on her 10th course and had been experiencing general malaise and appetite loss. At the onset of her current symptoms, her cumulative dose of 5-FU was 40.2 g. She had no known metastasis to the liver, nor did she have a history of liver disease.

Her Glasgow Coma Scale score on arrival was 10 on a scale of 15, with the following elements:

  • Eye opening 3 of 4 (opens eyes to sound)

  • Verbal response 1 of 5 (no response)

  • Motor response 6 of 6 (obeys commands).

Her eyes were deviated upward. She had urinary incontinence.

On arterial blood gas analysis, oxygen and carbon dioxide levels were normal; lactate was elevated (4.1 mmol/L) without acidemia (pH 7.445, bicarbonate 24.8 mmol/L).

Results of a complete metabolic panel revealed elevated serum ammonia (109 μg/dL) and blood urea nitrogen (23 mg/dL) levels, and normal levels of electrolytes, glucose, hepatobiliary markers, serum creatinine, and serum thiamine (27 ng/mL). A urine drug screening test was negative.

Electroencephalography showed diffuse slow and triphasic waves without epileptiform patterns.

Diffusion-weighted brain magnetic resonance imaging (MRI) showed symmetrical, bilateral high-intensity areas in the insular cortex, cingulate gyrus, and thalamus (Figure 1a).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

(A) Symmetrical, bilateral, high-intensity areas in the insular cortex, cingulate gyrus, and thalamus (arrows) on diffusion-weighted brain magnetic resonance imaging. (B) The high-intensity area in the thalamus disappeared and those in the insular cortex and cingulate gyrus decreased on hospital day 2.

5-FU was discontinued. Her mental status recovered, and MRI findings normalized by hospital day 2 (Figure 1b). Her symptoms were diagnosed as 5-FU–induced encephalopathy, and she was discharged on day 5. Her chemotherapy regimen was changed, and no mental status changes recurred.

5-FU–INDUCED ENCEPHALOPATHY

5-FU is one of the most widely used anticancer drugs. It can induce encephalopathy that presents with altered mental status or seizures, although this effect is rare, with an incidence of 0.6%.1 The encephalopathy can present as hyperammonemic encephalopathy, leukoencephalopathy, or Wernicke encephalopathy. Risk factors include azotemia, dehydration, and bacterial infection.2

Main mechanisms

Krebs cycle suppression, caused by fluoroacetate, a 5-FU catabolite, inhibits the adenosine triphosphate-dependent urea cycle, leading to hyperammonemia.3 This mechanism also produces lactic acid, causing hyperlactatemia.

Dihydropyrimidine dehydrogenase (DPD) deficiency. DPD is an enzyme involved in 5-FU catabolism. DPD deficiency leads to 5-FU accumulation, with neurotoxic effects such as demyelination.4 5-FU also increases cellular thiamine metabolism, thereby causing Wernicke encephalopathy.5

Although the DPD level was not measured in this case, the mechanism likely involved Krebs cycle suppression rather than DPD deficiency because serum ammonium and lactate levels were elevated.

Diagnosis and prognosis

The diagnostic criteria for 5-FU–induced encephalopathy include development of encephalopathy during or shortly after 5-FU administration, along with exclusion of other metabolic, somatic, and drug-related causes.6 The differential diagnosis includes stroke, nonconvulsive status epilepticus, other encephalopathy (eg, uremic, hepatic, drug-induced), infection, and psychogenic disorders. However, the history of recent 5-FU administration is crucial.

This disorder has a diverse MRI presentation. In the leukoencephalopathy type, the lesions are found in the deep white matter and corpus callosum.1 The gray matter, including the bilateral basal ganglia, thalamus, and para-sagittal frontal cortices can occasionally be involved, as in our patient.7 Regardless of the presentation, abnormal MRI findings improve after 5-FU is stopped.1,7 Bilateral, symmetrical lesions in the insular cortex and cingulate gyrus, as in our patient, are characteristics of hyperammonemic encephalopathy.8

Discontinuing 5-FU and providing supportive therapy usually lead to rapid symptom resolution,8 although fatal outcomes have been reported.9 Uridine triacetate, the antidote for 5-FU, has been proposed as a treatment for severe 5-FU toxicity and should be considered for severe cases.10

Acknowledgment

The authors would like to sincerely thank Ms. Ryoko Yoshida for editing the figure.

  • Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Lucato LT,
    2. McKinney AM,
    3. Short J,
    4. Teksam M,
    5. Truwit CL
    . Reversible findings of restricted diffusion in 5-fluorouracil neurotoxicity. Australas Radiol 2006;50(4):364–368. doi:10.1111/j.1440-1673.2006.01602.x
    OpenUrlCrossRefPubMed
  2. ↵
    1. Liaw CC,
    2. Wang HM,
    3. Wang CH, et al
    . Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 1999; 10(3):275–281. doi:10.1097/00001813-199903000-00004
    OpenUrlCrossRefPubMed
  3. ↵
    1. Koenig H,
    2. Patel A
    . Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 1970; 23(2):155–160. doi:10.1001/archneur.1970.00480260061008
    OpenUrlCrossRefPubMed
  4. ↵
    1. Diasio RB,
    2. Beavers TL,
    3. Carpenter JT
    . Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81(1):47–51. doi:10.1172/JCI113308
    OpenUrlCrossRefPubMed
  5. ↵
    1. Heier MS,
    2. Dornish JM
    . Effect of the fluoropyrimidines 5-fluorouracil and doxifluridine on cellular uptake of thiamin. Anticancer Res 1989;9(4):1073–1077. pmid:2530931
    OpenUrlPubMed
  6. ↵
    1. Yeh KH,
    2. Cheng AL
    . High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 1997;75(3):464–465. doi:10.1038/bjc.1997.79
    OpenUrlCrossRefPubMed
  7. ↵
    1. Lee WW,
    2. Kim JS,
    3. Son KR,
    4. Kwon HM
    . Atypical diffusion-restricted lesion in 5-fluorouracil encephalopathy. AJNR Am J Neuroradiol 2012;33(7):E102–E103. doi:10.3174/ajnr.A2781
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Mitani S,
    2. Kadowaki S,
    3. Komori A, et al
    . Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: a case series and review of the literature. Medicine (Baltimore) 2017; 96(22):e6874. doi:10.1097/MD.0000000000006874
    OpenUrlCrossRef
  9. ↵
    1. Lukaschek J,
    2. Nufer M,
    3. Maurer D, et al
    . Cardiotoxicity and neurotoxicity of high-dose continuous fluorouracil as a result of degradation compounds in the drug vials. J Clin Oncol 2004;22(24):5022–5025. doi:10.1200/JCO.2004.04.272
    OpenUrlCrossRefPubMed
  10. ↵
    1. Ma WW,
    2. Saif MW,
    3. El-Rayes BF, et al
    . Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer 2017;123(2):345–356. doi:10.1002/cncr.30321
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 87 (9)
Cleveland Clinic Journal of Medicine
Vol. 87, Issue 9
1 Sep 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
5-Fluorouracil–induced encephalopathy
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
5-Fluorouracil–induced encephalopathy
Yudai Yano, Akira Kuriyama
Cleveland Clinic Journal of Medicine Sep 2020, 87 (9) 532-533; DOI: 10.3949/ccjm.87a.19126

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
5-Fluorouracil–induced encephalopathy
Yudai Yano, Akira Kuriyama
Cleveland Clinic Journal of Medicine Sep 2020, 87 (9) 532-533; DOI: 10.3949/ccjm.87a.19126
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • 5-FU–INDUCED ENCEPHALOPATHY
    • Acknowledgment
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Tinea incognito
  • Prolonged venous filling time and dependent rubor in a patient with peripheral artery disease
  • Sarcoidosis with diffuse purplish erythematous plaques on the hands
Show more The Clinical Picture

Similar Articles

Subjects

  • Drug Therapy
  • Imaging
  • Neurology
  • Oncology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire